Universal Beteiligungs und Servicegesellschaft mbH Sells 41,705 Shares of Progyny, Inc. $PGNY

Universal Beteiligungs und Servicegesellschaft mbH reduced its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 35.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 75,626 shares of the company’s stock after selling 41,705 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.09% of Progyny worth $1,627,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Amalgamated Bank raised its position in shares of Progyny by 8.7% during the 3rd quarter. Amalgamated Bank now owns 23,008 shares of the company’s stock valued at $495,000 after acquiring an additional 1,833 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in Progyny in the third quarter valued at about $487,000. Versant Capital Management Inc increased its holdings in Progyny by 61.8% in the third quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock valued at $50,000 after purchasing an additional 894 shares during the last quarter. Nordea Investment Management AB lifted its stake in Progyny by 2.3% in the third quarter. Nordea Investment Management AB now owns 187,601 shares of the company’s stock valued at $3,955,000 after buying an additional 4,239 shares during the period. Finally, Bayforest Capital Ltd boosted its holdings in Progyny by 2,106.3% during the third quarter. Bayforest Capital Ltd now owns 35,058 shares of the company’s stock worth $754,000 after buying an additional 33,469 shares during the last quarter. 94.93% of the stock is owned by institutional investors.

Analyst Ratings Changes

PGNY has been the topic of a number of analyst reports. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Canaccord Genuity Group lifted their price target on shares of Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a research report on Monday, November 17th. BTIG Research restated a “buy” rating on shares of Progyny in a research report on Wednesday, January 21st. Finally, Citigroup upgraded Progyny to an “outperform” rating in a report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Progyny currently has an average rating of “Moderate Buy” and a consensus target price of $29.36.

Insider Buying and Selling

In other Progyny news, CFO Mark S. Livingston sold 21,303 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $25.50, for a total transaction of $543,226.50. Following the sale, the chief financial officer directly owned 48,358 shares of the company’s stock, valued at $1,233,129. The trade was a 30.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Peter Anevski acquired 79,500 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was bought at an average price of $24.29 per share, with a total value of $1,931,055.00. Following the acquisition, the chief executive officer directly owned 680,251 shares in the company, valued at $16,523,296.79. This represents a 13.23% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold 22,046 shares of company stock worth $561,691 over the last quarter. 9.40% of the stock is owned by corporate insiders.

Progyny Price Performance

PGNY opened at $23.87 on Friday. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of 37.89, a P/E/G ratio of 1.53 and a beta of 0.93. The business’s 50-day moving average price is $25.65 and its two-hundred day moving average price is $23.33. Progyny, Inc. has a 1 year low of $17.98 and a 1 year high of $28.75.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.06. The business had revenue of $313.35 million during the quarter, compared to the consensus estimate of $299.23 million. Progyny had a return on equity of 10.71% and a net margin of 4.46%.Progyny’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period last year, the company earned $0.11 earnings per share. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. Sell-side analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.